PPARG and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these results, PPARγ agonists do appear to alter CML patient lipid profiles; however, PPARγ regulates multiple cellular processes and so it remains unclear if the regulation of LDAPS, specifically, promotes survival in TKI-treated CML cells.